Abstract: The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

Abstract: The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof.

Abstract: A heterocyclic amide compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and a pharmaceutical use thereof. The heterocyclic amide compound and a pharmacologically acceptable salt thereof of the present invention have superior inhibitory action on chymase group in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be used for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.

Abstract: Heterocyclic amide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.

Abstract: A novel carboxylic acid compound having a condensed ring; which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.

Abstract: A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.

Abstract: An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --NR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3 or --NHSO.sub.2 R.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; an optical isomer thereof or art acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.

Abstract: A plurality of node apparatuses are connected by an optical transmission line. Each of the node apparatuses is assigned with a wavelength as an address different from the others. Therefore, when a first node apparatus transmits data to a second node apparatus, the data is of a wavelength corresponding to the address of the second node apparatus. The data transmission is carried out in a time slot defined by a frame pulse. The data of the corresponding wavelength is only received in the second node apparatus, and data of other wavelengths are passed through the second node apparatus. Consequently, media-access control is easily carried out independently in each node apparatus in an optical network system by using wavelength division multiplexing.

Abstract: A supervisory node (2) and non-supervisory nodes (3 through 9) are connected in a loop by an optical transmission path (1). Over the loop (1) are transferred optical signals having wavelengths of .lambda.1 through .lambda. n. An access right control packet 10 is transferred in the loop at the optical wavelength of .lambda.1. A node performing data transmission by line exchange writes its own node address (SA), the destination address (DA) and transmit reservation in the header of the access right control packet 10, and sends the packet out on the optical transmission path. The supervisory node 2 having received this access right control packet writes the wavelength to be used (.lambda.i) into the used wavelength field (UWL), and notifies the transmit and receive nodes of the choice of the wavelength. The transmit node sends data to the receive node by line exchange at the designated wavelength .lambda.i.

Abstract: An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.O, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --CN, --NR.sub.3 R.sub.4, --CONR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3, --NHSO.sub.2 R.sub.3 or --SR.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; or an acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.

Abstract: A control system for controlling an actuator and a display unit of an air-conditioner, and a method of adjusting the control system. An operational amplifier executes calculation on the basis of analogue data from a plurality of temperature-data input terminals. An output from the operational amplifier is sent to a microcomputer through an A/D converter. In a normal control mode, the microcomputer controls the display unit and the actuator of the air conditioner. The microcomputer executes also an adjusting mode in which the microcomputer controls the display unit to display an outut voltage from the operational amplifier. The microcomputer selects one of the modes to be executed in response to a mode signal from a mode-signal generator. A reference voltage is inputted to the operational amplifier from a reference-voltage generating circuit. The reference voltage is adjusted such that the output voltage from the operational amplifier displayed on the display unit is brought to a predetermined standard level.

Abstract: A sensor (27) is provided to sense the humidity at the inner surface of a window of a vehicle interior. When the sensed surface humidity is above a certain value, the possibility of the window being fogged arises and the proportion of outside air to recirculated air is increased to 100% to reduce the interior humidity. When the surface humidity is above a higher value, the interior air control system (5) is operated to reduce the interior humidity by increasing the amount of inlet air, the inlet air temperature, etc.